BioWorld

June 27, 2007

Genentech, Abbott Partner To Develop Oncology Drugs

Genentech Inc. is acting the pharma part in a deal with Abbott to advance the latter's Phase I-stage compounds ABT-263 and ABT-869, a Bcl-2 protein antagonist and VEGF receptor kinase inhibitor, respectively. (BioWorld Today) Read More

MediciNova Picks 2 Programs, Looks To Partner Most Others

Broader Comparison Finds More Specific Angiogenesis Markers

NewCo News: Cequent's RNAi Platform Draws Novartis Investment, Option

Generex Gears Up For Phase III Trial Of Oral-lyn Insulin Spray

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...